The effectiveness and safety of the use of ethylmethylhydroxypyridine of succinate in patients with acute ischemic stroke

Authors:
M.V. ZHURAVLEVA^1,2, I.A. SHCHUKIN³, M.S. FIDLER³, A.B. PROKOFIEV^1,2, S.Yu. SEREBROVA^1,2, N.S. VASYUKOVA⁴, E.Yu. DEMCHENKOVA¹, V.V. ARKHIPOV¹

¹Scientific Center for Expertise of Medicinal Products of the Ministry of Health of the Russian Federation, Moscow, Russia;
²I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
³N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
⁴Federal Scientific Center — All-Russian Research Institute of Experimental Veterinary Medicine named after K.I. Skryabin and Ya.R. Kovalenko of the Russian Academy of Sciences, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2020, Vol. 120, No. 12, Issue 2

Abstract:
Stroke remains one of the most pressing issues in modern medicine, being the leading cause of mortality and disability in the population. In the Russian Federation, there is extensive experience in the use of neurocytoprotectors in ischemic stroke. In real-life clinical practice, it is important to observe the conditions under which neuroprotection will be as safe and effective as possible. This review presents an analysis of the results of clinical studies on the efficacy and safety of ethylmethylhydroxypyridine succinate (Mexidol) in patients with acute ischemic stroke. Early (within the first 6 hours of stroke) use of the drug significantly improves the recovery dynamics and improves the outcome of the disease; with the use of the drug, accelerated regression of neurological disorders, improvement in vital functions and quality of life of patients were noted. Studies have demonstrated a high safety profile of ethylmethylhydroxypyridine succinate. Key words: ischemic stroke, thrombolytic therapy, clinical trials, disability, antioxidant system, ethylmethylhydroxypyridine succinate, Mexidol.